ABL Bio to Participate in 2024 JP Morgan Healthcare Conference

ABL Bio (ABL Bio) announced on the 21st that it will participate in the 42nd JP Morgan Healthcare Conference (JPMHC) held in San Francisco, California, USA, from January 8 to 11 next year (local time).

The 42nd JP Morgan Healthcare Conference [Image source=JP Morgan]

JPMHC is the world's largest pharmaceutical and bio healthcare event held every January. Global big pharma, emerging bio companies, and professional investors gather to discuss research and development, investment attraction, partnerships, and more. Since its founding, ABL Bio has attended the conference for eight years, seeking various business development opportunities.

At this event, ABL Bio plans to hold follow-up meetings with global pharmaceutical companies with whom it has been discussing various cooperation plans, explore potential partners with innovative technologies, and confirm global trends for next-generation drug development. The company will focus on discussions regarding its immuno-oncology pipeline, including 'ABL503,' 'ABL111,' and 'ABL103,' as well as discussions on the blood-brain barrier (BBB) shuttle platform 'Grabody-B' for the development of treatments for degenerative brain diseases.

Lee Sang-hoon, CEO of ABL Bio, said, “JPMHC is not only an event where we can have important face-to-face conversations with global company representatives whom we have met online so far, but also a place to check the latest trends that must be considered in new drug development all at once. Having achieved meaningful results through continuous participation in global events, we believe this conference will also be an important opportunity for ABL Bio's growth.”